Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: AProspective Study in the EPIC Cohort

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk : AProspective Study in the EPIC Cohort. / Lujan-Barroso, Leila; Botteri, Edoardo; Caini, Saverio; Ljungberg, Boerje; Roswall, Nina; Tjønneland, Anne; Bueno-de-Mesquita, Bas; Gram, Inger T.; Tumino, Rosario; Kiemeney, Lambertus A.; Liedberg, Fredrik; Stocks, Tanja; Gunter, Marc J.; Murphy, Neil; Cervenka, Iris; Fournier, Agnes; Kvaskoff, Marina; Haeggstroem, Christel; Overvad, Kim; Lund, Eiliv; Waaseth, Marit; Turzanski Fortner, Renee; Kuhn, Tilman; Menendez, Virginia; Sanchez, Maria-Jose; Santiuste, Carmen; Perez-Cornago, Aurora; Zamora-Ros, Raul; Cross, Amanda J.; Trichopoulou, Antonia; Karakatsani, Anna; Peppa, Eleni; Palli, Domenico; Krogh, Vittorio; Sciannameo, Veronica; Mattiello, Amalia; Panico, Salvatore; van Gils, Carla H.; Onland-Moret, N. Charlotte; Barricarte, Aurelio; Amiano, Pilar; Khaw, Kay-Tee; Boeing, Heiner; Weiderpass, Elisabete; Duell, Eric J.

In: Cancer Epidemiology, Biomarkers & Prevention, Vol. 29, No. 8, 2020, p. 1654-1664.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lujan-Barroso, L, Botteri, E, Caini, S, Ljungberg, B, Roswall, N, Tjønneland, A, Bueno-de-Mesquita, B, Gram, IT, Tumino, R, Kiemeney, LA, Liedberg, F, Stocks, T, Gunter, MJ, Murphy, N, Cervenka, I, Fournier, A, Kvaskoff, M, Haeggstroem, C, Overvad, K, Lund, E, Waaseth, M, Turzanski Fortner, R, Kuhn, T, Menendez, V, Sanchez, M-J, Santiuste, C, Perez-Cornago, A, Zamora-Ros, R, Cross, AJ, Trichopoulou, A, Karakatsani, A, Peppa, E, Palli, D, Krogh, V, Sciannameo, V, Mattiello, A, Panico, S, van Gils, CH, Onland-Moret, NC, Barricarte, A, Amiano, P, Khaw, K-T, Boeing, H, Weiderpass, E & Duell, EJ 2020, 'Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: AProspective Study in the EPIC Cohort', Cancer Epidemiology, Biomarkers & Prevention, vol. 29, no. 8, pp. 1654-1664. https://doi.org/10.1158/1055-9965.EPI-20-0184

APA

Lujan-Barroso, L., Botteri, E., Caini, S., Ljungberg, B., Roswall, N., Tjønneland, A., Bueno-de-Mesquita, B., Gram, I. T., Tumino, R., Kiemeney, L. A., Liedberg, F., Stocks, T., Gunter, M. J., Murphy, N., Cervenka, I., Fournier, A., Kvaskoff, M., Haeggstroem, C., Overvad, K., ... Duell, E. J. (2020). Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: AProspective Study in the EPIC Cohort. Cancer Epidemiology, Biomarkers & Prevention, 29(8), 1654-1664. https://doi.org/10.1158/1055-9965.EPI-20-0184

Vancouver

Lujan-Barroso L, Botteri E, Caini S, Ljungberg B, Roswall N, Tjønneland A et al. Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: AProspective Study in the EPIC Cohort. Cancer Epidemiology, Biomarkers & Prevention. 2020;29(8):1654-1664. https://doi.org/10.1158/1055-9965.EPI-20-0184

Author

Lujan-Barroso, Leila ; Botteri, Edoardo ; Caini, Saverio ; Ljungberg, Boerje ; Roswall, Nina ; Tjønneland, Anne ; Bueno-de-Mesquita, Bas ; Gram, Inger T. ; Tumino, Rosario ; Kiemeney, Lambertus A. ; Liedberg, Fredrik ; Stocks, Tanja ; Gunter, Marc J. ; Murphy, Neil ; Cervenka, Iris ; Fournier, Agnes ; Kvaskoff, Marina ; Haeggstroem, Christel ; Overvad, Kim ; Lund, Eiliv ; Waaseth, Marit ; Turzanski Fortner, Renee ; Kuhn, Tilman ; Menendez, Virginia ; Sanchez, Maria-Jose ; Santiuste, Carmen ; Perez-Cornago, Aurora ; Zamora-Ros, Raul ; Cross, Amanda J. ; Trichopoulou, Antonia ; Karakatsani, Anna ; Peppa, Eleni ; Palli, Domenico ; Krogh, Vittorio ; Sciannameo, Veronica ; Mattiello, Amalia ; Panico, Salvatore ; van Gils, Carla H. ; Onland-Moret, N. Charlotte ; Barricarte, Aurelio ; Amiano, Pilar ; Khaw, Kay-Tee ; Boeing, Heiner ; Weiderpass, Elisabete ; Duell, Eric J. / Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk : AProspective Study in the EPIC Cohort. In: Cancer Epidemiology, Biomarkers & Prevention. 2020 ; Vol. 29, No. 8. pp. 1654-1664.

Bibtex

@article{e4c1caf638ba4629a6998c2780b83bc8,
title = "Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: AProspective Study in the EPIC Cohort",
abstract = "Background: Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk.Methods: Weused an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models.Results: During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR= 5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscleinvasive urothelial carcinoma risk was observed.Conclusions: Our results support that increasing the number of FTP may reduce urothelial carcinoma risk.Impact: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.",
keywords = "BLADDER-CANCER RISK, SEX-HORMONES, ASSOCIATION, EXPRESSION, ESTROGEN, THERAPY, SMOKING, IMPACT, WOMEN, DIET",
author = "Leila Lujan-Barroso and Edoardo Botteri and Saverio Caini and Boerje Ljungberg and Nina Roswall and Anne Tj{\o}nneland and Bas Bueno-de-Mesquita and Gram, {Inger T.} and Rosario Tumino and Kiemeney, {Lambertus A.} and Fredrik Liedberg and Tanja Stocks and Gunter, {Marc J.} and Neil Murphy and Iris Cervenka and Agnes Fournier and Marina Kvaskoff and Christel Haeggstroem and Kim Overvad and Eiliv Lund and Marit Waaseth and {Turzanski Fortner}, Renee and Tilman Kuhn and Virginia Menendez and Maria-Jose Sanchez and Carmen Santiuste and Aurora Perez-Cornago and Raul Zamora-Ros and Cross, {Amanda J.} and Antonia Trichopoulou and Anna Karakatsani and Eleni Peppa and Domenico Palli and Vittorio Krogh and Veronica Sciannameo and Amalia Mattiello and Salvatore Panico and {van Gils}, {Carla H.} and Onland-Moret, {N. Charlotte} and Aurelio Barricarte and Pilar Amiano and Kay-Tee Khaw and Heiner Boeing and Elisabete Weiderpass and Duell, {Eric J.}",
year = "2020",
doi = "10.1158/1055-9965.EPI-20-0184",
language = "English",
volume = "29",
pages = "1654--1664",
journal = "Cancer Epidemiology, Biomarkers & Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research (A A C R)",
number = "8",

}

RIS

TY - JOUR

T1 - Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk

T2 - AProspective Study in the EPIC Cohort

AU - Lujan-Barroso, Leila

AU - Botteri, Edoardo

AU - Caini, Saverio

AU - Ljungberg, Boerje

AU - Roswall, Nina

AU - Tjønneland, Anne

AU - Bueno-de-Mesquita, Bas

AU - Gram, Inger T.

AU - Tumino, Rosario

AU - Kiemeney, Lambertus A.

AU - Liedberg, Fredrik

AU - Stocks, Tanja

AU - Gunter, Marc J.

AU - Murphy, Neil

AU - Cervenka, Iris

AU - Fournier, Agnes

AU - Kvaskoff, Marina

AU - Haeggstroem, Christel

AU - Overvad, Kim

AU - Lund, Eiliv

AU - Waaseth, Marit

AU - Turzanski Fortner, Renee

AU - Kuhn, Tilman

AU - Menendez, Virginia

AU - Sanchez, Maria-Jose

AU - Santiuste, Carmen

AU - Perez-Cornago, Aurora

AU - Zamora-Ros, Raul

AU - Cross, Amanda J.

AU - Trichopoulou, Antonia

AU - Karakatsani, Anna

AU - Peppa, Eleni

AU - Palli, Domenico

AU - Krogh, Vittorio

AU - Sciannameo, Veronica

AU - Mattiello, Amalia

AU - Panico, Salvatore

AU - van Gils, Carla H.

AU - Onland-Moret, N. Charlotte

AU - Barricarte, Aurelio

AU - Amiano, Pilar

AU - Khaw, Kay-Tee

AU - Boeing, Heiner

AU - Weiderpass, Elisabete

AU - Duell, Eric J.

PY - 2020

Y1 - 2020

N2 - Background: Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk.Methods: Weused an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models.Results: During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR= 5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscleinvasive urothelial carcinoma risk was observed.Conclusions: Our results support that increasing the number of FTP may reduce urothelial carcinoma risk.Impact: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.

AB - Background: Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk.Methods: Weused an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models.Results: During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR= 5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscleinvasive urothelial carcinoma risk was observed.Conclusions: Our results support that increasing the number of FTP may reduce urothelial carcinoma risk.Impact: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.

KW - BLADDER-CANCER RISK

KW - SEX-HORMONES

KW - ASSOCIATION

KW - EXPRESSION

KW - ESTROGEN

KW - THERAPY

KW - SMOKING

KW - IMPACT

KW - WOMEN

KW - DIET

U2 - 10.1158/1055-9965.EPI-20-0184

DO - 10.1158/1055-9965.EPI-20-0184

M3 - Journal article

C2 - 32467345

VL - 29

SP - 1654

EP - 1664

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

SN - 1055-9965

IS - 8

ER -

ID: 248848837